| Assessment Status | Rapid Review Complete |
| HTA ID | 21060 |
| Drug | Molnupiravir |
| Brand | Lagevrio® |
| Indication | For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 30/11/2021 |
| Rapid review completed | 24/12/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of molnupiravir compared with the current standard of care on the basis of the proposed price. |
